Last updated on January 2019

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's


Brief description of study

A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.

Detailed Study Description

A total of 525 eligible subjects with early untreated Parkinson's disease (PD), will be randomized to 4 treatment groups. Each subject will participate in the study for approximately 18 weeks including a 30 day screening period, 12 week treatment period, and 2 weeks follow-up period.

Clinical Study Identifier: NCT03329508

Find a site near you

Start Over

P2B001/003 Site Golden Valley

Golden Valley, MN United States
  Connect »

P2B001 Study site Edison

Edison, NJ United States
  Connect »

P2B001/003 Site Winfield

Winfield, IL United States
  Connect »

P2B001 study site Cincinnati

Cincinnati, OH United States
  Connect »

P2B001/003 New York

New York, NY United States
  Connect »

P2B001/003 Site Sarasota

Sarasota, FL United States
  Connect »

P2B001/003 Site Dallas

Dallas, TX United States
  Connect »

P2B001/003 Greenville

Greenville, SC United States
  Connect »

P2B001 Study site Syracuse

Syracuse, NY United States
  Connect »

P2B001/003 Site Port Charlotte

Port Charlotte, FL United States
  Connect »

P2B001 Study Vernon

Vernon, CT United States
  Connect »

P2B001/003 Site Scottsdale

Scottsdale, AZ United States
  Connect »

P2B001 site Los Angeles

Los Angeles, CA United States
  Connect »

P2B001/003 site Boca Raton

Boca Raton, FL United States
  Connect »

P2B001/003 Site Boca Raton

Boca Raton, FL United States
  Connect »

P2B001/003 site Miami

Miami, FL United States
  Connect »

P2B001/003 Site Tampa

Tampa, FL United States
  Connect »

P2B001/003 Site Augusta

Augusta, GA United States
  Connect »

P2B001/003 site Chicago

Chicago, IL United States
  Connect »

P2B001/003 site Kansas City

Kansas City, KS United States
  Connect »

P2B001/003 Site Lexington

Lexington, KY United States
  Connect »

P2B001/003 Site East Lansing

East Lansing, MI United States
  Connect »

P2B001/003 site St. Louis

Saint Louis, MO United States
  Connect »

P2B001/003 Site Commack

Commack, NY United States
  Connect »

P2B001/003 Site Asheville

Asheville, NC United States
  Connect »

P2B001/003 Site Toledo

Toledo, OH United States
  Connect »

P2B001/003 site Bedford

Bedford, TX United States
  Connect »

P2B001 Study site Englewood,

Englewood, CO United States
  Connect »

P2B001/003 Site Kirkland

Kirkland, WA United States
  Connect »

P2B001/003 Study site Williamsville

Williamsville, NY United States
  Connect »